3 recruiting, 2 completed, 2 not yet recruiting, 1 active not recruiting. 9 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 3, Completed 2, Not yet recruiting 2, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
Follow Anktiva: new trials by email Literature Review of Anktiva trials Research Report on Anktiva
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With Sepsis Nogapendekin alfa inbakicept (NAI), Placebo - Sepsis | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 50 | 2026-10-15 | 2026-09-25 |
| First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Ipilimumab, Nivolumab, Nogapendekin alfa inbakicept - Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 26 | 2026-07-07 | 2026-07-10 |
| NAI for Sepsis With Persistent Lymphopenia Nogapendekin alfa inbakicept (NAI), Standard of Care (SOC) - Sepsis, Septic Shock | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 50 | 2026-07-06 | 2026-05-11 |
| Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797) - Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2026-04-15 | 2026-05-08 | |
| A Study to Examine Anktiva for the Treatment of COVID-19. Anktiva - Long COVID, Long COVID Syndrome | Phase 2 | Recruiting | ImmunityBio, Inc. | 40 | 2025-09-04 | 2026-09-24 |
| N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma Bevacizumab, PD-L1 t-haNK, N-803 - Glioblastoma | Phase 2 | Active not recruiting | ImmunityBio, Inc. | 34 | 2024-08-07 | 2026-07-01 |
| PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC PD-L1 t-haNK, Cetuximab, NAI - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 25 | 2024-02-16 | 2026-10-19 |
| Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection M7824, N803, TriAd vaccine - Head and Neck Cancer, Head and Neck Neoplasms | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2020-06-09 | 2025-07-16 |
| Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) M7824, N-803, MVA-BN-Brachyury - Metastatic Castration-resistant Prostate Cancer, Prostate Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 59 | 2018-05-01 | 2025-09-30 |
Sepsis (3) · Critical Illness (2) · Head and Neck Neoplasms (2) · Lymphopenia (2) · Carcinoma, Non-Small-Cell Lung (1) · Community-Acquired Pneumonia (1) · Glioblastoma (1) · Post-Acute COVID-19 Syndrome (1) · Prostatic Neoplasms (1) · Respiratory Distress Syndrome (1) · Shock, Septic (1) · Squamous Cell Carcinoma of Head and Neck (1)
ImmunityBio, Inc. (5) · National Cancer Institute (NCI) (2) · Dana-Farber Cancer Institute (1) · Washington University School of Medicine (1)
United States (6)
Giordano Fabricio Cittolin Santos, MD, PhD (1) · Hoyoung Maeng, M.D. (1) · James L Gulley, M.D. (1) · Lennie Sender, MD (1) · Michael Dennis, MD (1)
PMID 30227893, PMID 33602696, PMID 33720067, PMID 35727629, PMID 40156838, PMID 42498485